Article de revue
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. The researchers studied infants 6 to 12 weeks of age recruited for the same trial.The study concludes that the RTS,S/AS01 vaccine coadministered with EPI vaccines provided modest protection against both clinical and severe malaria in young infants.
Langues
- Anglais
Année de publication
2012
Journal
The New England Journal of Medicine
Volume
367
Numéro
24
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Paludisme
Pays
- Afrique
Mots-clés
- Introduction de nouveaux vaccins
